Local Consolidative Therapy Conducted for Oligometastatic Non-small-cell Lung Cancer After Chemoimmunotherapy

DOI Web Site 14 References
  • Ide Shogo
    Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine
  • Eguchi Takashi
    Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine
  • Matsuoka Shunichiro
    Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine
  • Miura Kentaro
    Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine
  • Hamanaka Kazutoshi
    Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine
  • Tani Naoki
    Suwa Central Hospital
  • Onishi Hiroshi
    Kasugai CyberKnife Rehabilitation Hospital
  • Koizumi Tomonobu
    Department of Hematology and Medical Oncology, Shinshu University School of Medicine
  • Hanaoka Masayuki
    First Department of Internal Medicine, Shinshu University School of Medicine
  • Shimizu Kimihiro
    Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine

Bibliographic Information

Other Title
  • オリゴ転移非小細胞肺癌に対し化学・免疫療法後に局所地固め治療を行った1例

Search this article

Abstract

<p>Background. The efficacy of local consolidative therapy (LCT) for oligometastatic non-small-cell lung cancer (NSCLC) has been reported. However, the feasibility and prognostic impact of LCT following immunotherapy have been unknown. We herein report a patient who underwent immunotherapy followed by LCT for oligometastatic NSCLC. Case. A 66-year-old male former smoker presented with stage IV lung cancer in the right upper lobe and an oligometastasis in the right adrenal gland. The patient underwent chemoimmunotherapy, which resulted in a partial response. Right upper lobectomy with mediastinal lymph node dissection followed by stereotactic body radiotherapy (SBRT) with a CyberKnife for a right adrenal metastasis was planned as LCT. The surgery was provided 86 days after the chemoimmunotherapy due to the requirement of steroid therapy for arthritis as an immune-related adverse event (irAE). SBRT with a CyberKnife was conducted 58 days after the surgery. He has been alive without disease relapse for one year since the initiation of treatment. Conclusion. In general, there are multiple treatment choices, combinations, and orders for LCT; therefore, accumulating individual case experiences and sharing information on the outcomes is crucial. SBRT with a CyberKnife is one choice for LCT for oligometastasis of the adrenal gland. Care should be taken to complete surgery as LCT in patients with irAEs requiring steroid therapy.</p>

Journal

  • Haigan

    Haigan 63 (2), 115-121, 2023-04-20

    The Japan Lung Cancer Society

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top